Evidence map›Paper›PMID 37855713›Full record

ArticleParasite (Paris, France)2023

Seroepidemiology of toxoplasmosis in pregnant women and detection of infection acquired during pregnancy in Cotonou, Benin.

Richard Amagbégnon, Celia Dechavanne, Magalie Dambrun, Urielle Yehouénou, Noé Akondé, Florence Migot-Nabias, Aretas Babatoundé Nounnagnon Tonouhéwa, Azra Hamidović, Nadine Fievet, Angéline Tonato-Bagnan and 5 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Parasite (Paris, France), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Seroprevalence ofPathogens (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Richard AmagbégnonCentre Hospitalier Universitaire de la Mère et de l'Enfant-Lagune (CHU-MEL), 01 BP 107 Cotonou, Bénin - Institut de Recherche Clinique du Bénin (IRCB), Abomey-Calavi, Benin.
Celia DechavanneUniversité Paris Cité, MERIT, IRD, Paris, France.ORCID 0000-0001-8439-9976
Magalie DambrunUniversité Paris Cité, MERIT, IRD, Paris, France.
Urielle YehouénouCentre Hospitalier Universitaire de la Mère et de l'Enfant-Lagune (CHU-MEL), 01 BP 107 Cotonou, Bénin.
Noé AkondéCentre Hospitalier Universitaire de la Mère et de l'Enfant-Lagune (CHU-MEL), 01 BP 107 Cotonou, Bénin.
Florence Migot-NabiasUniversité Paris Cité, MERIT, IRD, Paris, France.ORCID 0000-0001-9982-594X
Aretas Babatoundé Nounnagnon TonouhéwaUnité de Recherche sur les Maladies Transmissibles (URMAT), Université d'Abomey-Calavi, 01 BP 2009, Cotonou, Bénin.
Azra HamidovićInserm U1094, IRD U270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidémiologie des maladies chroniques en zone tropicale, Institut d'Epidémiologie et de Neurologie Tropicale, OmegaHealth, Limoges, France.
Nadine FievetUniversité Paris Cité, MERIT, IRD, Paris, France.
Angéline Tonato-BagnanCentre Hospitalier Universitaire de la Mère et de l'Enfant-Lagune (CHU-MEL), 01 BP 107 Cotonou, Bénin - Université d'Abomey-Calavi (UAC), Faculté des Sciences de la Santé (FSS), Bénin.
Aurore Ogouyemi-HountoInstitut de Recherche Clinique du Bénin (IRCB), Abomey-Calavi, Benin - Université d'Abomey-Calavi (UAC), Faculté des Sciences de la Santé (FSS), Bénin - Service de Microbiologie du Centre National Hospitalier Universitaire - Hubert Koutoukou MAGA (CNHU-HKM) de Cotonou, Bénin.
Maroufou Jules AlaoCentre Hospitalier Universitaire de la Mère et de l'Enfant-Lagune (CHU-MEL), 01 BP 107 Cotonou, Bénin - Université d'Abomey-Calavi (UAC), Faculté des Sciences de la Santé (FSS), Bénin.
Marie-Laure DardéInserm U1094, IRD U270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidémiologie des maladies chroniques en zone tropicale, Institut d'Epidémiologie et de Neurologie Tropicale, OmegaHealth, Limoges, France - Centre National de Référence (CNR) sur la toxoplasmose/Toxoplasma Biological Resource Center (BRC), CHU de Limoges, 87042 Limoges, France.
Aurélien MercierInserm U1094, IRD U270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidémiologie des maladies chroniques en zone tropicale, Institut d'Epidémiologie et de Neurologie Tropicale, OmegaHealth, Limoges, France - Centre National de Référence (CNR) sur la toxoplasmose/Toxoplasma Biological Resource Center (BRC), CHU de Limoges, 87042 Limoges, France.ORCID 0000-0003-4332-5879
Dorothée Kindé-GazardInstitut de Recherche Clinique du Bénin (IRCB), Abomey-Calavi, Benin - Université d'Abomey-Calavi (UAC), Faculté des Sciences de la Santé (FSS), Bénin - Service de Microbiologie du Centre National Hospitalier Universitaire - Hubert Koutoukou MAGA (CNHU-HKM) de Cotonou, Bénin.
Université Paris Cité · FRClinical Research Institute · USInserm · FRUniversité d'Abomey-Calavi · BJCentre National Hospitalier et Universitaire Hubert Koutoukou MAGA · BJ

Funding

ANR 17-CE35-0004Bio-Mérieux
6 · The paper itself

Abstract

Assessing the prevalence of toxoplasmosis in pregnant women and the associated risk factors is the first step in defining policy for the prevention of congenital toxoplasmosis in a given population. An epidemiological study was conducted during prenatal consultations at the CHU-MEL of Cotonou (Benin) between September 2018 and April 2021 and recruited 549 pregnant women to determine the seroprevalence and potential factors associated with Toxoplasma gondii infection. Toxoplasma gondii IgG/IgM antibodies were detected using an enzyme-linked fluorescence assay (ELFA) technique, an IgG avidity test and an IgG/IgM comparative Western blot to diagnose the maternal toxoplasmosis serological status, the possibility of an infection acquired during pregnancy and congenital infection, respectively. Concomitantly, the participants answered a questionnaire investigating potential risk factors. Toxoplasmosis seroprevalence was estimated at 44.4% (95% CI 40.3-48.6) and the factors significantly associated with T. gondii seropositivity were: age over 30 years, multigravid women and contact with cats. The possibility of an infection acquired during the periconceptional period or the first trimester of pregnancy concerned six women [1.1% (95% CI 0.5-2.0)]. However, due to the low rate of serological controls in seronegative women, a significant proportion of women first tested during the 3rd trimester of pregnancy, and an insufficient sample size, the incidence of primary infection during pregnancy could not be determined. No cases of congenital transmission occurred in the newborns from the suspected cases of primary infection.

Indexed as

Pregnancy Complications, ParasiticToxoplasmaToxoplasmosisAdultAnimalsAntibodies, ProtozoanBeninCatsFemaleHumansImmunoglobulin GImmunoglobulin MInfant, NewbornPregnancyPregnant PeopleRisk FactorsAntibodies, ProtozoanImmunoglobulin GImmunoglobulin MBeninMaternal primary infectionPregnancySeroprevalenceSurveyToxoplasma gondii

Identifiers

PMID37855713
PMCPMC10586240
OpenAlexW4387764758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.